Cargando…
Breast Cancer Heterogeneity
Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468623/ https://www.ncbi.nlm.nih.gov/pubmed/34573897 http://dx.doi.org/10.3390/diagnostics11091555 |
_version_ | 1784573717971468288 |
---|---|
author | Fumagalli, Caterina Barberis, Massimo |
author_facet | Fumagalli, Caterina Barberis, Massimo |
author_sort | Fumagalli, Caterina |
collection | PubMed |
description | Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way. |
format | Online Article Text |
id | pubmed-8468623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84686232021-09-27 Breast Cancer Heterogeneity Fumagalli, Caterina Barberis, Massimo Diagnostics (Basel) Review Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way. MDPI 2021-08-27 /pmc/articles/PMC8468623/ /pubmed/34573897 http://dx.doi.org/10.3390/diagnostics11091555 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fumagalli, Caterina Barberis, Massimo Breast Cancer Heterogeneity |
title | Breast Cancer Heterogeneity |
title_full | Breast Cancer Heterogeneity |
title_fullStr | Breast Cancer Heterogeneity |
title_full_unstemmed | Breast Cancer Heterogeneity |
title_short | Breast Cancer Heterogeneity |
title_sort | breast cancer heterogeneity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468623/ https://www.ncbi.nlm.nih.gov/pubmed/34573897 http://dx.doi.org/10.3390/diagnostics11091555 |
work_keys_str_mv | AT fumagallicaterina breastcancerheterogeneity AT barberismassimo breastcancerheterogeneity |